Immunic (NASDAQ:IMUX) Coverage Initiated at Guggenheim

Research analysts at Guggenheim began coverage on shares of Immunic (NASDAQ:IMUX) in a research report issued on Tuesday, Marketbeat reports. The brokerage set a “buy” rating and a $7.00 price target on the stock. Guggenheim’s target price points to a potential upside of 430.30% from the stock’s current price.

Several other equities analysts have also issued reports on IMUX. HC Wainwright lowered their price target on Immunic from $8.00 to $5.00 and set a “buy” rating for the company in a research report on Monday, March 2nd. Weiss Ratings restated a “sell (e+)” rating on shares of Immunic in a research note on Monday, December 29th. raised shares of Immunic to a “strong-buy” rating in a report on Tuesday, February 3rd. Finally, D. Boral Capital dropped their target price on shares of Immunic from $8.00 to $4.00 and set a “buy” rating on the stock in a research note on Friday, February 13th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Immunic presently has an average rating of “Buy” and an average target price of $6.17.

Immunic Stock Up 5.6%

IMUX stock opened at $1.32 on Tuesday. The business has a 50 day moving average of $0.92 and a 200 day moving average of $0.80. The firm has a market cap of $172.21 million, a PE ratio of -1.89 and a beta of 1.46. Immunic has a twelve month low of $0.51 and a twelve month high of $1.51.

Immunic (NASDAQ:IMUX) last released its earnings results on Thursday, February 26th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.02). On average, research analysts expect that Immunic will post -0.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Qube Research & Technologies Ltd bought a new stake in Immunic in the 3rd quarter worth about $29,000. Focus Partners Wealth increased its holdings in Immunic by 1.5% during the third quarter. Focus Partners Wealth now owns 2,581,587 shares of the company’s stock valued at $2,276,000 after buying an additional 39,063 shares during the last quarter. Two Sigma Investments LP purchased a new stake in shares of Immunic in the 3rd quarter worth $52,000. Squarepoint Ops LLC lifted its position in Immunic by 29.9% during the fourth quarter. Squarepoint Ops LLC now owns 352,875 shares of the company’s stock valued at $188,000 after purchasing an additional 81,301 shares in the last quarter. Finally, Jane Street Group LLC lifted its position in Immunic by 46.8% during the fourth quarter. Jane Street Group LLC now owns 286,677 shares of the company’s stock valued at $153,000 after purchasing an additional 91,346 shares in the last quarter. 51.82% of the stock is owned by institutional investors.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.